Peptides DB
Research-centric peptide and protocol reference hub

Survodutide (BI 456906) record · updated 9h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 30 studiesJump to the evidenceCompare
What is Survodutide (BI 456906) used for?

Survodutide (BI 456906) is an investigational dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This peptide is primarily being studied for its potential in treating obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The dual action of Survodutide is designed to enhance weight loss while also improving glycemic control, which is particularly relevant for individuals with type 2 diabetes and related metabolic disorders.

How it works: GLP-1/glucagon receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Survodutide (BI 456906) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 82 registered trials. It describes the research record, not a recommendation.

Identity
NameSurvodutide (BI 456906)
Chain length—
Molecular weight4,232 Da
FormulaC192H289N47O61
Structure typeNot established
ClassMetabolic
Research levelWell Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 171378821. No verified residue count for this compound.

Pharmacology
MechanismGLP-1/glucagon receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 3, 2026. How this works →
Research stats
Total studies30
Human / animal / cellular14 / 5 / 2
Highest trial phasePhase 3
Years covered2019–2026
Latest study1mo ago
Publication history
20192026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

30 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Finding-8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.
Human2023Full text read0.90
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Finding18.7% body-weight reduction at 46 weeks.
review2026Full text read0.80
Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
FindingNot reported in abstract.
Animal2026Full text read0.70
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Finding-8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2
Human2026Full text read0.90
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Finding84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.
Human2026Full text read0.90
Survodutide Once Weekly for the Treatment of Adults with Obesity.
Finding-12.2% mean change in body weight from baseline in the 3.6-mg group at week 76, 95% CI -13.6 to -10.8.
Human2026Full text read0.90
Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
TakeawayNot reported in abstract.
—2026Title only0.10
Lactiplantibacillus plantarum as a multifunctional probiotic for inflammatory bowel disease: Mechanisms, synbiotic strategies, and delivery systems.
TakeawayLactiplantibacillus plantarum shows promise as a probiotic for IBD, but further research is needed to translate these findings into clinical practice.
review2026Full text read0.70
Deciphering the hydrogen shuttle-mediated kinetic memory of Ge-related defects in UV-grade fused quartz via in situ EPR with 3D imaging.
Finding20-fold increase in Ge-E' generation rate in subsequent UV cycles.
In vitro2026Full text read0.80
Strangulated Ileus Caused by Clips Used for Closure of an Appendiceal Endoscopic Submucosal Dissection Perforation: A Case Report.
FindingNot reported in abstract.
Human2026Full text read0.80
Architecture-driven engineered lattice tetrahedral micro-scaffolds for extraskeletal osteogenesis.
Findingmean BV/TV values of 9.05-12.74% at 12 weeks
Animal2026Full text read0.70
A dual-targeting mRNA lipid nanoparticle restores ABCA1-dependent cholesterol homeostasis to promote repair of age-related bone defects.
FindingNot reported in abstract.
Animal2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Survodutide (BI 456906) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Survodutide (BI 456906) is discussed should be drawn from it.